×
Featured
Want to learn more about Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!
Program Committee
-
Stella Blackburn, MD, MA, MSC, FFPM, FISPE, FRCP Strategy
Consultant, United Kingdom -
William Gregory, PHD Senior Director, Safety and Risk Management
Pfizer Inc, United States -
Catherine Baldridge, MSC Executive Dir., Head of Safety
Verdiva, United States -
Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President, Patient Safety Officer
Bristol Myers Squibb, United States -
Cheryl Campbell, MS Associate Director of Executive Operations/Outreach and Communications, OSE,CDER
FDA, United States -
Ingrid N. Chapman, PHARMD Senior Risk Management Analyst, DRM, OMEPRM, OSE, CDER
FDA, United States -
Mick Foy Director of Delivery
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom -
E. Stewart Geary, MD MD, Global Safety Officer
Eisai Co., Ltd., Japan -
Stephen Knowles, MD, MRCP Chief Medical Officer
Halozyme Therapeutics, United States -
Jill K. Logan, PHARMD Safety Evaluator, DPV I, OSE, CDER
FDA, United States -
Barbara Morollo, RN Head, Pharmacovigilance
Corbus Pharmaceuticals, United States -
Michael Richardson, MD, FFPM, FRCP Senior Vice President, WorldWide Patient Safety
Bristol-Myers Squibb, United Kingdom -
Annette Stemhagen, DrPH, PHD, FISPE Chief Science Officer
UBC, United States -
Lesley Wise, PHD, MSC Managing Director
Wise Pharmacovigilance and Risk Management, Ltd, United Kingdom -
Hui-Lee Wong, PHD, MS Epidemiologist, Sentinel Central Team, OBE, CBER
FDA, United States -
Jo Wyeth, PHARMD Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
FDA, United States
Have an account?